Skip to main content
S&P 5007,773.95+0.66%DOW51,267.90+0.18%NASDAQ27,477.31+1.05%BTC$85,823.00-0.87%ETH$2,714.23-0.50%GOLD$4,166.20+0.23%OIL$89.41-0.02%
Smart Investors Daily
SID Premium
IO

NASDAQ · IONS

Ionis Pharmaceuticals, Inc.

Healthcare · Biotechnology

$43.50

Down-$0.04 (-0.09%)

Updated Oct 6, 2026, 5:50 AM

SID Score

4.2/10

Composite research score

Smart Money

58/100

Neutral

Market cap
12.57B
P/E ratio
-49.61
Dividend yield
0.00%
52-week range
$43.01 – $86.74
Volume
2.87M
Avg. volume
2.43M

Price performance · IONS

IONS price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

IONS closed at $43.50 after 20 trading sessions, down 23.29% for the selected period.

Last close
$43.50
Period change
-23.29%
Period low
$43.50
Period high
$56.71
Daily close
View OHLC price history
IONS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$43.75$43.96$42.63$43.502.87M
Oct 2, 2026$44.17$44.17$43.24$43.542.31M
Oct 1, 2026$44.63$45.95$43.963$44.002.03M
Sep 30, 2026$46.07$46.245$44.60$44.652.63M
Sep 29, 2026$45.53$46.46$45.39$45.893.89M
Sep 28, 2026$44.56$46.945$44.06$45.573.74M
Sep 25, 2026$44.245$45.28$43.62$44.506.2M
Sep 24, 2026$43.77$44.60$43.25$43.816.45M
Sep 23, 2026$46.23$46.41$43.0065$43.933.54M
Sep 22, 2026$44.96$46.13$44.44$45.754.24M
Sep 21, 2026$44.945$45.25$44.20$44.904.52M
Sep 18, 2026$46.75$46.75$44.27$44.447.37M
Sep 17, 2026$46.68$47.42$45.75$46.754.08M
Sep 16, 2026$47.38$47.59$44.66$44.847.96M
Sep 15, 2026$51.37$51.37$46.715$47.256.81M
Sep 14, 2026$54.88$55.50$51.31$51.445.97M
Sep 11, 2026$55.94$56.16$54.16$54.212.18M
Sep 10, 2026$55.75$55.77$54.91$55.653.06M
Sep 9, 2026$56.38$56.9569$55.695$56.023.04M
Sep 8, 2026$52.15$57.4292$52.15$56.719.18M

Latest IONS news

The latest Smart Investors Daily articles mentioning IONS.

Stock researchCompany · Overview

IONS research

Overview

Company profile and research snapshot.

Company profile

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$83.85
Implied upside
—
Analysts
—
IONS recent ratings
DateFirmRatingTarget
Sep 24, 2026HC Wainwright & Co.Buy—
Sep 22, 2026JP MorganOverweight—
Sep 15, 2026GuggenheimBuy—
Sep 9, 2026BarclaysOverweight—
Sep 8, 2026Morgan StanleyOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 25, 2026

Ionis Pharmaceuticals (IONS) Stock Looks Pricey On Its 45% YTD Slide

Ionis Pharmaceuticals has had a rough run so far this year, even as fresh clinical results have put its drug pipeline in the spotlight. With the share price under pressure, the real issue for investors is how well the current valuation lines up with the sales its business is generating and may be able to support over time. The stock is down about 45.0% year to date. This puts a sharp spotlight on whether today's market value still lines up with what Ionis can justify through its sales...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By